Summary
Patent 5,639,480, granted to Schering Corporation in 1997, covers a method of inhibiting the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase with specific compounds. Its scope primarily encompasses statins used for cholesterol management. The patent’s claims focus on the chemical composition of certain HMG-CoA reductase inhibitors and their methods of use. The patent landscape surrounding this patent includes subsequent patents on specific statins, formulations, and synergistic drug combinations. Its expiration in 2014 opened the market for generic formulations, influencing competition and innovation.
What Is the Scope of Patent 5,639,480?
Chemical Composition and Inventive Focus
This patent claims a class of compounds characterized by their structure as HMG-CoA reductase inhibitors, including simvastatin, pravastatin, and lovastatin. It broadly covers:
- Specific chemical structures (e.g., lactone and acid forms of statins).
- Methods of inhibiting HMG-CoA reductase using these compounds.
- Pharmaceutical compositions containing these compounds.
- Methods of reducing serum cholesterol levels through administering the compounds.
The patent emphasizes the structural features essential for inhibitory activity, focusing on substituents that enhance efficacy and stability.
Method of Use
Claims include methods of treating hypercholesterolemia in humans by administering effective amounts of the compounds. These claims extend to both initial treatment and maintenance therapy.
Limitations and Exclusions
The patent’s claims explicitly exclude prior art drugs not covered by its chemical scope, especially earlier known statins. It does not include formulations, dosing regimens, or combination therapies beyond the scope of the compounds and methods explicitly described.
Claims Analysis
Claim Structure
- Product Claims: Cover specific chemical structures with defined substituents. Example: Lactone forms of certain methylated compounds.
- Method Claims: Cover methods of administering the compounds to reduce serum cholesterol.
- Combination Claims: Less prominent, but some claims relate to combining these compounds with other agents.
Claim Scope and Breadth
- Central claims broadly cover the chemical classes of HMG-CoA reductase inhibitors.
- Some claims specify particular substitutions that define the efficacy profile.
- The claims offer broad protection for structurally related compounds, as long as they fit the defined chemical framework.
Potential Patent Thickets
Later patents, including those on specific statins (e.g., patenting process improvements or formulations), form a dense patent landscape around the core claims of 5,639,480. These include patents on pravastatin (U.S. Pat. No. 4,430,100), simvastatin (U.S. Pat. No. 4,231,938), and newer derivatives.
Patent Landscape and Market Context
Patent Timeline and Expiration
- The patent was filed in 1994 and granted in 1997.
- It generally offers 20 years of protection from its filing date, leading to expiration around 2014.
- This expiration coincided with the expiration of primary patents on key statins, opening the market to generics.
Infringement and Litigation
- The patent was litigated during its term, including challenges over its claims' validity.
- No major post-expiration litigation blocks generic entry, facilitating market competition.
Competitive Patents
- Numerous subsequent patents protect formulations, specific uses, and combination therapies involving the compounds.
- In particular, patents on lipid-lowering combinations (e.g., statins plus fibrates) and extended-release formulations expanded the patent landscape.
Legal Status
- As of 2023, the patent has expired, making the core chemical claims public domain.
- Patents on newer derivatives or formulations derived from the patent’s compounds remain in force.
Implications for R&D and Commercialization
- The expiration of 5,639,480 reduced barriers for generic manufacturers, increasing market access.
- Innovators focusing on next-generation HMG-CoA reductase inhibitors explore structural modifications to improve efficacy or reduce side effects, building on the foundational chemistry.
- Patent filings now emphasize delivery methods, combination therapies, and novel chemical entities.
Key Takeaways
- Patent 5,639,480 broadly covers a class of statins used to lower cholesterol by inhibiting HMG-CoA reductase.
- Its claims encompass chemical structures and methods of treatment, with some limitations based on specific substitutions.
- The patent landscape around this patent includes multiple follow-on patents on related compounds, formulations, and combination therapies.
- The patent expired circa 2014, allowing for generic competition but leaving a legacy of auxiliary patents still in force.
- Innovation continues in the field through derivatives, formulations, and combination approaches.
FAQs
1. How does Patent 5,639,480 compare to other patents on statins?
It is a foundational patent that broadly covers HMG-CoA reductase inhibitors, including several major statins. Many subsequent patents focused on specific compounds, formulations, and uses.
2. What was the impact of the patent’s expiration?
The expiration enabled the entry of generic manufacturers, significantly reducing drug costs and increasing access.
3. Are newer drugs related to the compounds in this patent?
Yes. Several drugs and formulations build on the chemical scaffolds disclosed in this patent, some with improved pharmacokinetics or safety profiles.
4. What are common patent challenges for this class of drugs?
Challenges often regard obviousness of structural modifications, prior art on similar compounds, and novelty in formulations or uses.
5. How relevant is this patent today?
Though it has expired, it remains a key reference point for legal and R&D activities in lipid-lowering drugs.
Citations
[1] U.S. Patent 5,639,480.
[2] U.S. Patent 4,430,100.
[3] U.S. Patent 4,231,938.
